Please login to the form below

heart attack patients

This page shows the latest heart attack patients news and features for those working in and with pharma, biotech and healthcare.

Novartis plans inclisiran trial in the UK

Novartis also plans to conduct ORION-4, the ongoing study for patients who have already had a heart attack or stroke, with this study making the UK the global trial centre. ... In January, Novartis announced that it has teamed up with the NHS which will

Latest news

AZ says Brilinta hits the mark in new stroke trial

When used on its own by patients who had already suffered a stroke or transient ischaemic attack (TIA), it demonstrated a trend towards fewer subsequent events of stroke, heart attack ... The drug is already approved for the treatment of acute coronary
Amarin files fish oil-based heart drug Vascepa in Europe

The EU filing comes as Vascepa (icosapent ethyl) is also under review by the FDA for a new label claim that the drug can reduce the incidence of heart attack and ... with Vascepa “major adverse cardiovascular events such as stroke, heart attack and
Mistrust of pharma still blocking NHS collaborations

The benefits of well-managed and well-targeted joint working projects to patients and the NHS – and pharma - are widely accepted on both sides, but these remain relatively few and far ... Examples of successful joint initiatives include one between
Amgen and UCB’s Evenity finally approved, but with label warnings

But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it’s important to carefully select patients for this therapy, which includes avoiding use in patients who ... The label also notes that doctors should consider
Novartis withdraws EU filing for canakinumab

The company has completed a phase 3 study of canakinumab as a treatment to prevent stroke and myocardial infarction (MI) or death in patients who have already suffered a heart attack - ... This showed that injections of canakinumab every three months

More from news
Approximately 1 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Proving real-world value

Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”. ... We create thousands of patient leaflets
Patient collaborations

Published: 21 Nov 2011. AZ’s patient support programme provided holistic support to newly diagnosed heart attack patients. ... Improve discharge information. Maximise adherence to medication. Address psychological health. AstraZeneca also launched a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Understanding the "Big Picture"

In this case, of the male patients with ACS, 27% experienced angina and 73% experienced a heart attack. ... This quickly demonstrates that the majority of male patients who experience a heart attack will be found within the non ST-elevated heart attack

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.